AROMICS receives 1 Million Euros to advance in its therapy for cancer
Malignant Mesothelioma is an aggressive, poor prognosis and highly refractory cancer. It is also known as the "asbestos cancer", as this mineral widely used at the industrial settings over the past century, is the main origin of the tumour. The published new established an important milestone for AROMICS. The company has received EU H2020 funding for advancing in a new therapy to treat this devastating cancer.